Alert detail

LCD L39680: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — Noridian

Policy ID: LCD-L39680Specialty: PulmonologyAdded: 6/5/2026Effective: September 22, 2024lcd
High

What changed

New guidelines may improve billing for pulmonary nodule tests.

Who’s affected: Pulmonology billing teams · Effective: September 22, 2024

Affected codes

Codes81479

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 6 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Pulmonology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Pulmonology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Pulmonology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L39680: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — Noridian